Pathstone Holdings’s SpringWorks Therapeutics SWTX Stock Holding History

Pathstone Holdings’s Portfolio SWTX Stock Details SWTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-33,301	Closed	-$1.56M	–	2405
2025 Q2	$1.56M	Sell	33,301 -7,920	-19%	-$352K	0.01%	1136
2025 Q1	$1.82M	Buy	41,221 +23,544	+133%	+$1.08M	0.01%	1036
2024 Q4	$639K	Buy	17,677 +1,346	+8%	+$47K	﹤0.01%	1622
2024 Q3	$523K	Buy	16,331 +5,040	+45%	+$188K	﹤0.01%	1708
2024 Q2	$425K	Buy	+11,291	New	+$475K	﹤0.01%	1778

Other funds holding SWTX

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Pathstone Holdings's SWTX Position: Q3 2025 in Review

Pathstone Holdings sold out of SpringWorks Therapeutics (SWTX) in Q3 2025, closing a stake of 33,301 shares — an estimated $1.56M sold.

Pathstone Holdings first reported a position in SWTX in Q2 2024 and held it in 5 quarters. The position peaked at $1.82M in Q1 2025. 3 funds tracked by Wall St. Rank hold SWTX as of Q3 2025.

Pathstone Holdings reported no remaining SpringWorks Therapeutics position as of Q3 2025 after selling out during the quarter.
Pathstone Holdings sold 33,301 SpringWorks Therapeutics shares in Q3 2025, an estimated $1.56M.
Pathstone Holdings first reported a position in SpringWorks Therapeutics in Q2 2024 and held it in 5 quarters.
Pathstone Holdings's SpringWorks Therapeutics position peaked at $1.82M in Q1 2025.
3 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q3 2025.

Based on Pathstone Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.